论文部分内容阅读
目的通过大肠癌患者在化疗前和化疗结束时的肝功能检验指标的变化以及其与HLA-DRB1、HLA-DQB1多态性的关联,以期找到大肠癌化疗副损伤的相关基因。方法选取100例大肠癌患者,采用多聚酶链反应-序列特异性引物(PCR-SSP)法检测其HLA-DRB1、HLA-DQB1的多态性。同时检测大肠癌患者化疗前和化疗结束时的肝功能检验指标,包括TBIL、DBIL、TP、ALB、ALT、AST、ALP、GGT。结果 HLA-DRB1*07有可能是化疗对ALT、GGT损伤的抵抗基因;HLA-DRB1*08有可能是化疗对ALT损伤的抵抗基因;HLA-DRB1*09有可能是化疗对ALB、ALT、GGT损伤的抵抗基因;HLA-DRB1*12有可能是化疗对ALB、ALT损伤的抵抗基因;HLA-DQB1*02有可能是化疗对ALT损伤的抵抗基因,同时HLA-DQB1*02也可能是化疗对AST损伤的敏感基因;HLA-DQB1*05有可能是化疗对ALB损伤的抵抗基因;HLA-DQB1*06有可能是化疗对ALT、GGT损伤的抵抗基因。结论 HLA可能是肿瘤化疗副损伤的标志性基因。
Objective To detect the changes of liver function tests and the association with HLA-DRB1, HLA-DQB1 polymorphisms in patients with colorectal cancer before chemotherapy and at the end of chemotherapy so as to find out the genes related to chemotherapy-induced side effects of colorectal cancer. Methods 100 cases of colorectal cancer were selected and the polymorphisms of HLA-DRB1 and HLA-DQB1 were detected by polymerase chain reaction-sequence-specific primers (PCR-SSP). At the same time, the indexes of liver function testing including the TBIL, DBIL, TP, ALB, ALT, AST, ALP and GGT before and at the end of chemotherapy were detected simultaneously in patients with colorectal cancer. Results HLA-DRB1 * 07 may be the resistance gene of chemotherapy for ALT and GGT injury. HLA-DRB1 * 08 may be the resistance gene for chemotherapy-induced ALT injury. HLA-DRB1 * HLA-DRB1 * 12 may be the resistance gene to chemotherapy of ALT and ALT; HLA-DQB1 * 02 may be the resistance gene of chemotherapy against ALT injury, and HLA-DQB1 * 02 may also be the chemotherapy HLA-DQB1 * 05 may be the resistance gene of ALB injury induced by chemotherapy; HLA-DQB1 * 06 may be the resistance gene of chemotherapy for ALT and GGT damage. Conclusion HLA may be a landmark gene for chemotherapy-induced side effects.